Rosetta Genomics (ROSG) Continues Recent Surge
Tweet
Share
E-mail
Get Alerts ROSG Hot Sheet
Join SI Premium – FREE
Rosetta Genomics, Ltd. (Nasdaq: ROSG) is seeing sharp upside today. Shares are up 16 percent currently to $8.62.
Shares have been en fuego since May 16th when the company announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview mets assay, informed Rosetta that it plans to cover this assay for all Medicare beneficiaries.
A direct equity offering following that huge May 16th pop slowed the stock down for a day, but it has been all uphill since.
Shares have been en fuego since May 16th when the company announced that Novitas, the designated Medicare Administrative Contractor for the Company's miRview mets assay, informed Rosetta that it plans to cover this assay for all Medicare beneficiaries.
A direct equity offering following that huge May 16th pop slowed the stock down for a day, but it has been all uphill since.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Krystal Biotech to join S&P MidCap 400, Tutor Perini and V2X to join S&P SmallCap 600
- Goldman sees buying opportunity in beaten-down software name
- U.S. Business and Information Services: Q2 earnings preview
Create E-mail Alert Related Categories
Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
